Investor 2018-01-05T15:54:27+00:00

Investor Relations

An opportunity to invest in the new first line treatment option for all health professional prescribers and recommenders.

Life-Changing Technology

  • Pelviva® offers the first clinically effective practical treatment via a consumer healthcare solution
  • A single use, disposable treatment for UI
  • Unique and proven technology
  • Easy to use and fits in with women’s lifestyles
  • No drug related side effects

Large and Growing Market

  • Urinary incontinence is a highly prevalent condition affecting women across the globe
  • The ageing demographic means that it is a fast-growing market
  • Pelviva – potential to be a $1bn+ global opportunity

Projected High Investment Returns

  • Femeda’s market analyses and business modelling project a highly profitable investment opportunity.
  • The device is a 12 week course of treatment which creates a professional and retail opportunity to sell a 45 unit course of treatment as part of brand strategy to maximise sales and profit.

Launch April 2018

  • Pelviva® has been subject to an exhaustive research and development programme.
  • The product has full CE accreditation.
  • 26 granted patents across 4 patented groups with extensive geographical coverage to 2035.
  • Manufacturing capacity has been thoroughly tested.
  • Post marketing clinical study to deliver enhanced clinical data

Experienced Management Team

  • The board of directors at Femeda offer an impressive depth of experience and record of success.